Lornamead
This article was originally published in The Rose Sheet
Executive Summary
George Russell tapped CEO for company's North American division, following firm's recent acquisition of the Finesse and Aqua Net brands from Unilever, Lornamead Group announces June 7. Reporting to CEO of Lornamead Group Mike Jatania, Russell will oversee company's product development, manufacturing, distribution and marketing activities in North America, Central and South America, firm notes. Among his goals for the division, Russell notes he will guide the company in reinvesting in and reinvigorating the already well-established hair care brands, and will look for opportunities to acquire additional brands. Lornamead recently stated it hopes to build a $500 mil. personal care business in North America in the next three to five years (1"The Rose Sheet" May 15, 2006, In Brief)...
You may also be interested in...
Lornamead
UK company aims to build approximately $500 mil. personal care business in North America in the next three to five years, CEO Mike Jatania says, noting segment is now in excess of $100 mil. with the recent acquisition of Finesse and Aqua Net (1"The Rose Sheet" May 8, 2006, p. 6). In the next 60 days, Lornamead will consult with retailers, conduct focus groups and appoint public relations and advertising agencies to develop its marketing program for the brands, according to Jatania. In November, firm will launch new products under Yardley personal care brand, which was acquired from Procter & Gamble last year, exec adds. Company also markets Natural White teeth whitening products and Lypsyl lip balm...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.